GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

Germany-based RNA therapy developer CureVac signed a strategic partnership agreement with pharmaceutical firm GlaxoSmithKline (GSK) today that will include a €150m ($176m) equity investment.

GSK will also make a $141m upfront cash payment to CureVac and a reimbursable one-time payment of $35m to secure manufacturing capacity upon certification of a facility the company currently has under construction. The deak will give GSK a 10% stake in CureVac.

Spun out of Eberhard Karls University of Tübingen in 2000, CureVac is developing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn